New Treatments for Type 2 Diabetes and Chronic Kidney Disease Approved, Alongside Advances in AI for Space and Longevity Research

The reported developments are primarily positive advancements in medical treatments and scientific research, with no immediate or elevated risks identified.

📌 Key developments

• FDA Approves New Chronic Kidney Disease Treatment for Type 1 Diabetes: Bayer announced that the U.S. Food and Drug Administration (FDA) has approved KERENDIA (finerenone), a non-steroidal mineralocorticoid receptor antagonist (MRA), as the first new treatment in over 30 years for adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D). This oral, once-daily medication is expected to reduce the urinary albumin-to-creatinine ratio (UACR), which is a marker for kidney damage, and slow the progression of CKD. This matters because CKD is a serious complication for many with type 1 diabetes, and this approval offers a new option to protect kidney health, a widely feared condition among many, including Iranian readers. This treatment is now FDA-approved and available.
• Breakthroughs in Type 2 Diabetes Management with Triple-Action Medications and AI-Powered Insulin Systems: 2026 is seeing the introduction of triple-action receptor agonists that simultaneously control blood sugar (glucose), promote weight loss, and protect cardiovascular health for people with type 2 diabetes (T2D). Additionally, smart insulin delivery systems are now integrating artificial intelligence (AI) algorithms to predict glucose fluctuations hours in advance, automatically adjusting insulin delivery based on various factors like continuous glucose monitoring data, meal timing, physical activity, and sleep cycles. This matters because type 2 diabetes is a widespread and often feared condition, and these innovations offer more comprehensive and personalized control, potentially reducing complications like heart disease, which is also a significant concern. These new medications and AI-powered systems are becoming available in 2026, with some already FDA-approved.
• AI-Based Space Surveillance System Under Development in Korea: Hanwha Systems has begun developing Korea's national space situational awareness system, or K-SSA, which combines artificial intelligence (AI) with surveillance satellites. This system aims to proactively monitor and analyze collision risks and falling debris from the rapidly increasing number of low-Earth orbit satellites, enhancing space security. This matters because the growing congestion in space poses risks to satellites and space missions, and AI-powered systems can significantly improve our ability to track and mitigate these threats. This is a development project, with the company handling satellite development and ground-linked system construction, and is expected to strengthen Korea's independent space security infrastructure.
• Epigenetic Reprogramming Enters First Human Trial for Longevity Research: Life Biosciences has received Investigational New Drug (IND) clearance from the FDA to test ER-100, an epigenetic reprogramming therapy, in human patients with optic neuropathies. This marks the first human trial of a cellular reprogramming technology, which uses three of the four Yamanaka factors (Oct4, Sox2, and Klf4) delivered locally to the eye. This matters because epigenetic reprogramming aims to reverse age-related cellular changes, offering a potential pathway to combat aging and age-related diseases, including those affecting vision. This is an early-stage human trial, meaning it is years away from potential widespread availability, and the fourth Yamanaka factor, c-Myc, was deliberately excluded due to its association with tumor formation.
• Dietary Changes Show Early Signs of Reducing Biological Age in Older Adults: New research from the University of Sydney, published in Aging Cell, found that Australians aged 65 to 75 who reduced either dietary fat or animal-based protein showed signs of a lower biological age after just four weeks. Biological age is an estimate of how old the body appears based on its health and physiological condition, rather than chronological age. This matters because it suggests that dietary interventions could quickly influence aging-related health markers, offering a relatively simple and accessible strategy for promoting healthier aging. These are preliminary findings from a short-term study, and longer studies are needed to confirm if these changes persist, translate into a lower risk of age-related disease, or apply to other populations.
• AI Toolkit for Longevity Research Released by Insilico Medicine: Insilico Medicine, a biotechnology company using generative artificial intelligence (AI), has published a landmark study in Cell introducing an open AI toolkit, including LongevityBench, Longevity-LLMs, and LongevityClaw. This toolkit is designed to accelerate research and therapeutic development in aging and longevity. This matters because AI can significantly speed up the discovery process for new drugs and interventions by analyzing vast biological datasets, potentially leading to breakthroughs in extending healthy lifespan. The toolkit aims to provide a common foundation for measuring progress in AI-enabled aging research and help distinguish genuine biological reasoning from mere data reproduction.
• New Hair Loss Treatment Combining Microneedling with Exosome Therapy Emerges: The most advanced treatment for hair loss in 2026 is microneedling combined with exosome therapy. This approach focuses on restoring scalp health and reactivating weakened hair follicles by delivering growth factors and proteins directly to the follicles. This matters because hair loss, or androgenetic alopecia, is a widely known and often feared condition among many, including Iranian readers, and this offers a non-surgical, regenerative approach to improve hair density and quality. This treatment is available now, but it works best when follicles are still present and is not a miracle cure for complete baldness.
• Molecular Map of Hypertrophic Cardiomyopathy Created: Researchers have created a detailed molecular map of hypertrophic cardiomyopathy (HCM), a condition where the heart muscle thickens and stiffens, potentially leading to heart failure or sudden cardiac arrest. Published in Science Translational Medicine, this work reveals differences between genetic and non-genetic HCM, as well as early and late stages of the disease, and identified a gene called PRR16 that may contribute to heart-cell enlargement. This matters because heart disease is a major global health concern, and this deeper understanding of HCM's molecular changes could inform the development of more targeted and effective treatments. This is foundational research, not yet a direct treatment, but it provides crucial insights for future therapies.
• Four to Six Servings of Wholegrain Daily Linked to Reduced Heart Disease Risk Factors: A new systematic review and meta-analysis published in the European Heart Journal found that eating four to six servings of wholegrain food each day reduces several major risk factors for cardiovascular disease, including body weight, blood pressure, and levels of cholesterol and glucose in the blood. The research, led by Dr. Helda Tutunchi from Tabriz University of Medical Sciences, Iran, combined data from 87 clinical trials. This matters because heart disease is a leading cause of death globally, and this strong evidence provides clear dietary guidance for preventing it. This is a confirmed nutritional finding, and increasing wholegrain intake is a simple, accessible, and affordable dietary strategy that can be implemented now.

💡 Why it matters

These developments are crucial for public health, offering improved treatments for widespread conditions like diabetes, heart disease, and hair loss. The advancements in AI for space surveillance and longevity research signal a future with enhanced security and potentially longer, healthier human lives, impacting resource allocation and strategic planning in health and technology sectors.

🎭 People in the news

• Dr. Helda Tutunchi — Led the research from Tabriz University of Medical Sciences on wholegrain intake and heart disease risk.
• Glenn Smith, Ph.D. — Co-leads the 1Florida Alzheimer's Disease Research Center, which received a renewed $22.3 million grant to advance early diagnosis and treatment of Alzheimer's.
• Dr. Manel Esteller — Head of the Cancer Epigenetics group at the Josep Carreras Leukaemia Research Institute, who led the detailed study of Maria Branyas, a woman who lived past 117, to understand extreme human longevity.

👀 What to watch

• Further clinical trial results for epigenetic reprogramming therapies in humans.
• Updates on the integration and real-world effectiveness of AI-powered diabetes management systems.
• Continued monitoring of the development and deployment of AI-based space surveillance systems.